Whitehawk Q2 2026 earnings: Cash runway extends into the second half of 2028
Whitehawk Therapeutics reported no revenue in Q2 2026, but significantly narrowed its net loss per share to $0.20 due to the absence of a large prior-year license fee. A private placement boosted cash reserves to $190.0 million, extending the company's cash runway into the …